0000921895-20-002557.txt : 20201007 0000921895-20-002557.hdr.sgml : 20201007 20201007194755 ACCESSION NUMBER: 0000921895-20-002557 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201004 FILED AS OF DATE: 20201007 DATE AS OF CHANGE: 20201007 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Graham Camilla CENTRAL INDEX KEY: 0001827543 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36866 FILM NUMBER: 201229896 MAIL ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Summit Therapeutics Inc. CENTRAL INDEX KEY: 0001599298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-514-7149 MAIL ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Summit Therapeutics plc DATE OF NAME CHANGE: 20150219 FORMER COMPANY: FORMER CONFORMED NAME: Summit Corp plc DATE OF NAME CHANGE: 20140205 4 1 form412566002_10072020.xml OWNERSHIP DOCUMENT X0306 4 2020-10-04 0 0001599298 Summit Therapeutics Inc. SMMT 0001827543 Graham Camilla ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142 0 1 0 0 Chief Clinical Affairs Officer Stock Option (right to buy) 3.34 2020-10-04 4 A 0 400000 3.34 A 2030-10-04 Common Stock 400000 400000 D The option was granted on October 4, 2020 pursuant to the Company's 2020 Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on October 4, 2021, subject to the satisfaction of certain performance targets. /s/ Michael Paul Donaldson, Attorney-in-Fact 2020-10-07